It is targeted primarily at SLE, true, and not even all of those patients will benefit. But from what I’ve seen of long-term continuation studies, for the patients in whom it works, it WORKS, reducing flare activity pretty close to zero.
There are also other auto-immune indications that this could potentially be used for; studies for those indications are either underway or going to launch soon. It’ll be a lot easier to get approvals for other indications than it was to get original approval, and I imagine there’ll be off-label use as well.
Your words are encouraging for my daughter. She was diagnosed 6 months ago at age 11. Overall her symptoms are mild but she has still missed lots of school this year over mysterious ailments.
I am not sure about your meaning of “other auto-immune” indicators. Are there new drugs being developed that build on this drug?